

## Second Opinion: Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following drug descriptions best reflects the mechanism of action of saruparib?
  - Androgen receptor pathway inhibitor
  - PARP1-selective inhibitor
  - AKT inhibitor
  - EZH2 inhibitor
- Which of the following statements best characterizes outcomes by degree of PTEN deficiency in the Phase III CAPItello-281 study evaluating capivasertib with abiraterone and androgen deprivation therapy (ADT) versus abiraterone/ADT alone for patients with de novo PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC)?
  - Higher degrees of PTEN loss appear to correlate with worse outcomes in both treatment arms
  - Degree of PTEN loss does not appear to correlate with the degree of benefit with capivasertib
  - Higher degrees of PTEN loss appear to correlate with better outcomes among patients who received the capivasertib regimen
  - Patients were not stratified by degree of PTEN loss in the study
- Long-term efficacy results from the placebo-controlled Phase III PROpel trial of olaparib and abiraterone as first-line treatment for metastatic castration-resistant prostate cancer demonstrated which radiographic progression-free survival (rPFS) outcome?
  - The greatest rPFS benefit was observed among patients with homologous recombination repair (HRR) mutations
  - Similar rPFS benefit was observed between patients with HRR mutations and those with BRCA mutations
  - The greatest rPFS benefit was observed among patients with BRCA mutations
- Which of the following testing methods is best suited for detecting PTEN deficiency?
  - FISH (fluorescence in situ hybridization)
  - IHC (immunohistochemistry)
  - Next-generation sequencing
  - All of the above methods are equally effective
- The ongoing Phase III EvoPAR-Prostate01 trial is evaluating saruparib in combination with physician's choice of next-generation hormonal agents for which patients with mHSPC?
  - Only patients with HRR-mutant tumors
  - Only patients with HRR-nonmutant tumors
  - Both patients with HRR-mutant and those with HRR nonmutant tumors